Venosin retard

Hauptinformation

  • Handelsname:
  • Venosin retard 50 mg - Kapseln
  • Einheiten im Paket:
  • 20 Stück, Laufzeit: 60 Monate,60 Stück, Laufzeit: 60 Monate
  • Verschreibungstyp:
  • Arzneimittel zur Abgabe ohne aerztliche Verschreibung
  • Verwenden für:
  • Menschen
  • Art der Medizin:
  • Pflanzliches für Menschengebrauch

Dokumenten

Lokalisierung

  • Erhältlich in:
  • Venosin retard 50 mg - Kapseln
    Österreich
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiebereich:
  • Other capillary stabilizi
  • Produktbesonderheiten:
  • Abgabe durch eine (öffentliche) Apotheke

Weitere Informationen

Status

  • Quelle:
  • AGES
  • Zulassungsnummer:
  • 14148
  • Berechtigungsdatum:
  • 20-06-1969
  • Letzte Änderung:
  • 10-08-2017

Packungsbeilage

GEBRAUCHSINFORMATION: INFORMATION FÜR ANWENDER

Venosin retard 50 mg - Kapseln

Wirkstoff: Trockenextrakt aus Rosskastaniensamen.

Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme

dieses Arzneimittels beginnen, denn sie enthält wichtige Informationen.

Nehmen Sie dieses Arzneimittel immer genau wie in dieser Packungsbeilage beschrieben

bzw. genau nach Anweisung Ihres Arztes oder Apothekers ein.

Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals

lesen.

Fragen Sie Ihren Apotheker, wenn Sie weitere Informationen oder einen Rat benötigen.

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker.

Dies gilt auch für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben

sind. Siehe Abschnitt 4.

Wenn Sie sich nicht besser oder gar schlechter fühlen, wenden Sie sich an Ihren Arzt.

Was in dieser Packungsbeilage steht:

Was ist Venosin retard und wofür wird es angewendet?

Was sollten Sie vor der Einnahme von Venosin retard beachten?

Wie ist Venosin retard einzunehmen?

Welche Nebenwirkungen sind möglich?

Wie ist Venosin retard aufzubewahren?

Inhalt der Packung und weitere Informationen

1.

WAS IST VENOSIN RETARD UND WOFÜR WIRD ES ANGEWENDET?

Venosin

retard

wirkt

natürlichen

Wirkstoff

Rosskastaniensamenextrakts

Ödemen (Flüssigkeitsansammlungen im Körpergewebe) entgegen. Aescin, der wirksame

Bestandteil des Rosskastaniensamenextrakts, strafft den Venenquerschnitt, verringert die

Gefäßdurchlässigkeit und fördert den venösen Blutabstrom und die Blutzirkulation bis in die

kleinsten Gefäße.

Venosin retard hemmt bei regelmäßiger Einnahme den Übertritt von Blutbestandteilen aus

Gefäßen

Gewebe,

hemmt

also

Bildung

Ödemen

bzw.

wirkt

dieser

Ödembildung vorbeugend entgegen.

Venosin retard wird angewendet bei Funktionsstörungen bei oder infolge von Erkrankungen

der Beinvenen (Symptome der chronischen Veneninsuffizienz) z.B.

Krampfadern

Venenentzündung (Phlebitis und Thrombophlebitis)

mit Beschwerden wie

Schmerzen in den Beinen

Schweregefühl

Juckreiz

nächtliche Wadenkrämpfe

Beinschwellung

Spannungsgefühl

Beinmüdigkeit

Flüssigkeitsansammlung im Gewebe (Ödeme)

Wenn Sie sich nicht besser oder gar schlechter fühlen, wenden Sie sich an Ihren Arzt.

2.

WAS SOLLTEN SIE VOR DER EINNAHME VON VENOSIN RETARD BEACHTEN?

Venosin retard darf nicht eingenommen werden,

wenn Sie allergisch gegen Rosskastaniensamen Trockenextrakt oder einen der in

Abschnitt 6. genannten sonstigen Bestandteile dieses Arzneimittels sind.

Warnhinweise und Vorsichtsmaßnahmen

Bitte sprechen Sie mit Ihrem Arzt oder Apotheker bevor Sie Venosin retard einnehmen.

Beim Auftreten einer Entzündung der Haut, einer oberflächlichen Venenentzündung, einer

subkutanen Verhärtung, von starken Schmerzen, von Geschwüren, ein plötzliches

Anschwellen eines oder beider Beine, einer Herz- oder Nierenschwäche während der

Anwendung von Venosin retard sollte ein Arzt konsultiert werden.

Hinweis

Weitere vom Arzt verordnete Maßnahmen, wie z. B. Wickeln der Beine, Tragen von

Stützstrümpfen oder kalte Wassergüsse, sollten unbedingt eingehalten werden.

Kinder und Jugendliche

Da keine ausreichenden Daten zur Sicherheit vorliegen, soll Venosin retard nicht Kindern

und Jugendlichen unter 18 Jahren verabreicht werden.

Einnahme von Venosin retard zusammen mit anderen Arzneimitteln

Einzelfällen

wurde

Wirkungsverstärkung

gerinnungshemmender

Arzneimittel

beobachtet. Bei gleichzeitiger Einnahme von solchen Mitteln ist die Blutgerinnung häufiger

zu kontrollieren.

Informieren

Ihren

Arzt

oder

Apotheker,

wenn

andere

Arzneimittel

einnehmen/anwenden, kürzlich andere Arzneimittel eingenommen/angewendet haben oder

beabsichtigen andere Arzneimittel einzunehmen/anzuwenden.

Schwangerschaft und Stillzeit

Wenn Sie schwanger sind oder stillen, oder wenn Sie vermuten, schwanger

zu sein oder beabsichtigen, schwanger zu werden, fragen Sie vor der Einnahme Ihren Arzt

oder Apotheker.

Venosin

retard darf in der Schwangerschaft und Stillzeit nicht angewendet werden, da hierzu

keine klinischen Studien durchgeführt wurden.

Verkehrstüchtigkeit und Fähigkeit zum Bedienen von Maschinen

Venosin retard hat keinen Einfluss auf die Verkehrstüchtigkeit und die Fähigkeit zum

Bedienen von Maschinen.

3.

WIE IST VENOSIN RETARD EINZUNEHMEN?

Nehmen Sie dieses Arzneimittel immer genau wie in dieser Packungsbeilage beschrieben

bzw. genau nach der mit Ihrem Arzt oder Apotheker getroffenen Absprache ein. Fragen Sie

bei Ihrem Arzt oder Apotheker nach, wenn Sie sich nicht sicher sind.

Die empfohlene Dosis beträgt:

Erwachsene:

Falls vom Arzt nicht anders verordnet, ist die übliche Dosis:

Morgens und abends je 1 Kapsel.

Anwendung bei Kindern und Jugendliche:

Die Anwendung bei Kindern und Jugendlichen unter 18 Jahren ist nicht vorgesehen.

Art der Anwendung

Die Einnahme erfolgt unzerkaut mit reichlich Flüssigkeit vor dem Essen.

Sollten leichte Magen- oder Darmbeschwerden auftreten empfiehlt es sich, das Arzneimittel

zu den Mahlzeiten einzunehmen.

Dauer der Anwendung

Die Dauer der Einnahme hängt von den Beschwerden ab. Grundsätzlich besteht keine

zeitliche Begrenzung der Anwendungsdauer. Bei Anhalten der Beschwerden sollte mit einem

Arzt über die Fortsetzung der Behandlung Rücksprache genommen werden.

Wenn Sie eine größere Menge von Venosin retard eingenommen haben, als Sie sollten

Die in Rosskastaniensamenextrakt enthaltenen Saponine können bei Überdosierung das als

Nebenwirkung bekannte Symptom Übelkeit verstärken, weiterhin sind Erbrechen und

Durchfälle möglich. Zur Entscheidung, ob Gegenmaßnahmen gegebenenfalls erforderlich

sind, sollte ein Arzt aufgesucht werden.

Wenn Sie die Einnahme von Venosin retard vergessen haben

Nehmen Sie nicht die doppelte Menge ein, wenn Sie die vorherige Einnahme vergessen

haben.

Wenn Sie die Einnahme von Venosin retard abbrechen

Eine Unterbrechung oder vorzeitige Beendigung der Behandlung ist in der Regel

unbedenklich. Im Zweifelsfalle befragen Sie hierzu bitte Ihren Arzt oder Apotheker.

Wenn Sie weitere Fragen zur Anwendung dieses Arzneimittels haben, wenden Sie sich an

Ihren Arzt oder Apotheker.

4.

WELCHE NEBENWIRKUNGEN SIND MÖGLICH?

Wie alle Arzneimittel kann auch dieses Arzneimittel Nebenwirkungen haben, die aber nicht

bei jedem auftreten müssen.

Bei der Bewertung von Nebenwirkungen werden folgende Häufigkeitsangaben zugrunde

gelegt:

Sehr häufig: kann mehr als 1 von 10 Behandelten betreffen

Häufig: kann bis zu 1 von 10 Behandelten betreffen

Gelegentlich: kann bis zu 1 von 100 Behandelten betreffen

Selten: kann bis zu 1 von 1 000 Behandelten betreffen

Sehr selten: kann bis zu 1 von 10 000 Behandelten betreffen

Nicht bekannt: Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar

Erkrankungen des Gastrointestinaltrakts:

Gelegentlich:

Übelkeit, Erbrechen, Durchfall, Magen- und Darmbeschwerden.

Erkrankungen des Nervensystems:

Gelegentlich:

Schwindel und Kopfschmerzen

Herzerkrankungen:

Sehr selten:

Beschleunigter Herzschlag und Blutdruckerhöhung

Überempfindlichkeitsreaktionen:

Selten:

Überempfindlichkeitsreaktionen der Haut (Juckreiz, Hautausschlag, Hautrötung,

Ekzem)

Sehr selten:

Schwerwiegende allergische Reaktionen (in einigen Fällen mit Blutungen)

Erkrankungen der Geschlechtsorgane und der Brustdrüse:

Sehr selten:

gynäkologische Zwischenblutungen

Meldungen von Nebenwirkungen

Wenn Sie Nebenwirkungen bemerken, wenden Sie sich an Ihren Arzt oder Apotheker. Dies

gilt auch für Nebenwirkungen, die nicht in dieser Packungsbeilage angegeben sind.

Sie können Nebenwirkungen auch direkt über das nationale Meldesystem anzeigen:

Bundesamt für Sicherheit im Gesundheitswesen

Traisengasse 5

1200 WIEN

ÖSTERREICH

Fax: + 43 (0) 50 555 36207

Website: http://www.basg.gv.at/

Indem Sie Nebenwirkungen melden, können Sie dazu beitragen, dass mehr Informationen

über die Sicherheit dieses Arzneimittels zur Verfügung gestellt werden.

5.

WIE IST VENOSIN RETARD AUFZUBEWAHREN?

Bewahren Sie dieses Arzneimittel für Kinder unzugänglich auf.

Sie dürfen dieses Arzneimittel nach dem auf dem Umkarton und dem Blister angegebenen

Verfalldatum nicht mehr verwenden. Das Verfalldatum bezieht sich auf den letzten Tag des

angegebenen Monats.

Aufbewahrungsbedingungen

Nicht über 25° C lagern. In der Orginalverpackung aufbewahren.

Das Arzneimittel darf nicht im Abwasser oder Haushaltsabfall entsorgt werden. Fragen Sie

Ihren Apotheker wie das Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr benötigen.

Diese Maßnahme hilft die Umwelt zu schützen.

6.

INHALT DER PACKUNG UND WEITERE INFORMATIONEN

Was Venosin retard enthält

Der Wirkstoff ist: Trockenextrakt aus Rosskastaniensamen.

1 Kapsel enthält Rosskastaniensamenextrakt entsprechend 50 mg Triterpenglykoside,

berechnet als wasserfreies β-Aescin.

Die sonstigen Bestandteile sind:

Dextrin, Copovidon, Talk, Eudragit, Triethylcitrat, Gelatine, Eisenoxid schwarz, rot und gelb E

172, Titandioxid E171, Indigokarmin E 132, Chinolingelb E 104

Wie Venosin retard aussieht und Inhalt der Packung

Venosin retard sind Hartkapseln mit transparent grünem Kapselunterteil und braunem

opaken Kapseloberteil,

Packungen mit 20 bzw. 60 Kapseln.

Pharmazeutischer Unternehmer

Klinge Pharma GmbH

Bergfeldstraße 9

83607 Holzkirchen

Deutschland

Hersteller

Swiss Caps GmbH

Grassingerstraße 9

83043 Bad Aibling

Sidroga Gesellschaft für Gesundheitsprodukte mbH

Arzbacher Straße 78

D-56130 Bad Ems

Z. Nr. 14148

Diese Gebrauchsinformation wurde zuletzt überarbeitet im 05/2017

3-4-2018

Three new reimbursement guidelines

Three new reimbursement guidelines

The Danish Medicines Agency has issued three new guidelines on reimbursement (in Danish only). This regards Guideline on application for general reimbursement and general conditional reimbursement, Guideline on periodic reassessment of the reimbursement status of medicines and Guideline on the making of health economic analyses of medicines.

Danish Medicines Agency

11-12-2017

Semenax capsules (counterfeit version)

Semenax capsules (counterfeit version)

Safety Alert- Semenax capsules (counterfeit version)

Therapeutic Goods Administration - Australia

16-1-2014

Reimbursement of medicines bought in another EU/EEA country

Reimbursement of medicines bought in another EU/EEA country

From 1 January 2014, you can obtain reimbursement of prescription-only medicines bought in another EU/EEA country under the general reimbursement rules of the Danish Health Act. You have to be covered by the national health insurance in Denmark and have a health insurance card (the yellow card) and the medicine must be reimbursable in Denmark.

Danish Medicines Agency

8-3-2012

Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"

Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"

We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.

Danish Medicines Agency

6-3-2012

Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

Comments received on the reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

The Danish National Board of Health has received a number of comments from stakeholders about the Reimbursement Committee's discussion of the reimbursement status of antidiabetic medicines (ATC group A10).

Danish Medicines Agency

22-2-2012

Decision on general conditional reimbursement for alendronate-containing medicines

Decision on general conditional reimbursement for alendronate-containing medicines

In cooperation with the Reimbursement Committee, we have decided to grant alendronate-containing medicines general conditional reimbursement from 5 March 2012. Reimbursement is conditional as it is reserved for patients with low-energy hip fractures. For any other patients who are treated with alendronate, the doctor must apply for single reimbursement, and the guiding criteria for single reimbursement remain unchanged for these patients. Alendronate is used for the treatment of osteoporosis (brittle bon...

Danish Medicines Agency

22-2-2012

Changed criteria for single reimbursement for osteoporosis medicines other than alendronate

Changed criteria for single reimbursement for osteoporosis medicines other than alendronate

As of 5 March 2012, it will only be possible to obtain a single reimbursement grant for the other medicines used in osteoporosis treatment for patients that cannot use alendronate. The criteria for single reimbursement are changed because of the large price gaps between the different medicines, where the reimbursement price of alendronate is by far the lowest.

Danish Medicines Agency

2-2-2012

Applications for general reimbursement in 2011

Applications for general reimbursement in 2011

In 2011, we reviewed 21 applications for general reimbursement for 20 different medicinal products. 15 of the applications ended with the granting of general reimbursement or general conditional reimbursement, and the remaining six applications were refused.

Danish Medicines Agency

25-1-2012

Review concluded regarding general reimbursement for Xarelto®

Review concluded regarding general reimbursement for Xarelto®

The Danish Medicines Agency has completed its review of an application for general reimbursement for two new strengths of Xarelto®. The product maintains general reimbursement.

Danish Medicines Agency

20-1-2012

Review concluded regarding general reimbursement for Zomig Nasal®

Review concluded regarding general reimbursement for Zomig Nasal®

The Danish Medicines Agency has completed its review of an application for general reimbursement for Zomig Nasal®. The product has been granted general reimbursement.

Danish Medicines Agency

17-1-2012

Decision on general reimbursement for Yellox®

Decision on general reimbursement for Yellox®

The Danish Medicines Agency has completed its review of an application for general reimbursement for Yellox®. The product has been granted general reimbursement.

Danish Medicines Agency

16-1-2012

Review concluded regarding general reimbursement for Multaq®

Review concluded regarding general reimbursement for Multaq®

The Danish Medicines Agency has completed its review of an application for general reimbursement for Multaq®. The product is neither eligible for general nor general conditional reimbursement.

Danish Medicines Agency

13-1-2012

Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

Reassessment of reimbursement status of antidiabetic medicines (ATC group A10)

On 22 December 2009, the Danish Medicines Agency announced that we would begin our reassessment of the reimbursement status of a number of groups of medicines, including antidiabetics (ATC group A10). Within a few months, the Reimbursement Committee will begin to discuss the reimbursement status of antidiabetics.

Danish Medicines Agency

5-1-2012

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.

Danish Medicines Agency

4-11-2011

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

Comments received on the reassessment of reimbursement status of strong analgesics (opioids)

The Danish Medicines Agency has received a number of comments for the Reimbursement Committee's discussion of reimbursement status of strong analgesics (opioids). These comments were presented to the Reimbursement Committee at its meeting on 27 September 2011. The Reimbursement Committee is currently processing a recommendation.

Danish Medicines Agency

7-10-2011

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

Changed reimbursement for medicines for depression and anxiety as of 5 March 2012

With effect from 5 March 2012, the reimbursement is changed for certain medicinal products for treatment of depression and anxiety (antidepressants and anxiolytics). Based on the Reimbursement Committee's recommendation, the Danish Medicines Agency has decided that in future the general rule is that treatment with inexpensive medicines (e.g. sertraline and citalopram) must be attempted before reimbursement can be granted for more expensive medicines (e.g. escitalopram, duloxetine, pregabalin and agomelat...

Danish Medicines Agency

4-10-2011

The reimbursement for glucosamine is removed on 28 November 2011

The reimbursement for glucosamine is removed on 28 November 2011

The Reimbursement Committee and the Danish Medicines Agency have reassessed the reimbursement status of glucosamine-containing medicines. We have decided to remove the reimbursement for these over-the-counter medicines on 28 November 2011. Glucosamine is used for the alleviation of painful osteoarthritis.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of glucosamine-containing medicines

The Reimbursement Committee’s recommendation on the future reimbursement status of glucosamine-containing medicines was open for consultation until 8 August 2011. The Danish Medicines Agency received 4 consultation responses.

Danish Medicines Agency

20-9-2011

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (ACT group N06A, etc.)

The Reimbursement Committee’s recommendation on the future reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B was open for consultation until 15 August 2011. The Danish Medicines Agency received 9 consultation responses.

Danish Medicines Agency

26-8-2011

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

Reassessment of reimbursement status of strong analgesics (opioids) – methadone and codeine

On 15 August 2011, the Danish Medicines Agency announced that we would begin reassessing the reimbursement status of medicines in ATC group N02A, opioids. The Reimbursement Committee opened its preliminary discussions at its meeting on 23 August 2011 and recommended to include the opioids methadone (N07BC02) and codeine (R05DA04), also used in pain management, in the reassessment of reimbursement status of medicinal products in ATC group N02A.

Danish Medicines Agency

15-8-2011

Reassessment of reimbursement status of strong analgesics (opioids)

Reassessment of reimbursement status of strong analgesics (opioids)

On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N (nervous system) starting with the ATC subgroup N06A (antidepressants) and then N02A (opioids). The Reimbursement Committee is having the initial discussions of the opioids at its meeting on 23 August 2011.

Danish Medicines Agency

5-7-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines in ATC group C01 (cardiac therapy)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group C01 – cardiac therapy. These medicines are used for the treatment of cardiac arrhythmia (e.g. atrial fibrillation) and heart cramps (angina pectoris).

Danish Medicines Agency

28-6-2011

Decision on future reimbursement status of medicines in ATC group C05 (vasoprotectives)

Decision on future reimbursement status of medicines in ATC group C05 (vasoprotectives)

On 27 June 2011, the Danish Medicines Agency decided on the future reimbursement status of medicines in ATC group C05 (vasoprotectives). These medicines will still not be eligible for general reimbursement.

Danish Medicines Agency

27-5-2011

Consultation on the Reimbursement Committee's recommendation for glucosamine

Consultation on the Reimbursement Committee's recommendation for glucosamine

The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.

Danish Medicines Agency

6-5-2011

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.

Danish Medicines Agency

3-3-2011

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)

The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)

Clinical studies have called into question the efficacy of glucosamine for the alleviation of painful osteoarthritis. This has contributed to the Danish Medicines Agency’s decision to initiate ad hoc reassessment of glucosamine-containing medicines, which today have general conditional reimbursement when prescribed for the alleviation of symptoms of mild to moderate osteoarthritis and when prescribed to old-age pensioners.

Danish Medicines Agency

11-1-2011

Reassessment of reimbursement status of medicines for treatment of depression and anxiety disorders

Reassessment of reimbursement status of medicines for treatment of depression and anxiety disorders

On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N

Danish Medicines Agency

14-6-2010

Changes in reimbursements for anti-ulcer medicines

Changes in reimbursements for anti-ulcer medicines

The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of heartburns, sour eructations and ulcers ('acid-related disorders') in order to assess whether they meet the criteria for public reimbursement.

Danish Medicines Agency

14-6-2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.

Danish Medicines Agency

3-6-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.

Danish Medicines Agency

21-4-2010

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.

Danish Medicines Agency

9-4-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders) was open for consultation until 15 March 2010.

Danish Medicines Agency

31-3-2010

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

7-1-2010

The Danish Medicines Agency initiates the reassessment of reimbursement status of medicines in ATC group N

The Danish Medicines Agency initiates the reassessment of reimbursement status of medicines in ATC group N

The Danish Medicines Agency initiates its reassessment of the reimbursement status of medicines in ATC group N (Nervous system). It will take place concurrently with the reassessment process for the remaining subgroups in ATC groups A and J.

Danish Medicines Agency

17-12-2009

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders)

At the request of the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status of medicinal products in ATC group A02 (drugs for acid related disorders).

Danish Medicines Agency

1-12-2009

Decision on future reimbursement status of medicinal products in ATC groups A04 and A03FA

Decision on future reimbursement status of medicinal products in ATC groups A04 and A03FA

On 25 November 2009, the Danish Medicines Agency made a decision on the future reimbursement status of medicinal products in ATC group A04 (antiemetics and antinauseants) and medical products in ATC group A03FA (propulsives)

Danish Medicines Agency

5-10-2009

Decision on future reimbursement status for medicinal products in ATC group C04 (peripheral vasodilators)

Decision on future reimbursement status for medicinal products in ATC group C04 (peripheral vasodilators)

On 21 September 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group (peripheral vasodilators).

Danish Medicines Agency

2-10-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C05 (Vasoprotectives)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C05 (Vasoprotectives).

Danish Medicines Agency

8-9-2009

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

On 3 september 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds).

Danish Medicines Agency

4-8-2009

Decision on the future reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

Decision on the future reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

On 3 July 2009, the Danish Medicines Agency made a decision on the future reimbursement status of medicinal products in ATC group A08 (antiobesity preparations excl. diet products).

Danish Medicines Agency

30-6-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C04 (Peripheral vasodilators)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group C04 (Peripheral vasodilators)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group C04 (Peripheral vasodilators)

Danish Medicines Agency

30-6-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives)

At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC groups A04 (antiemetics and antinauseants) and A03FA (propulsives).

Danish Medicines Agency

9-6-2009

Changes in reimbursement for cardiovascular medicine as of 13 July 2009

Changes in reimbursement for cardiovascular medicine as of 13 July 2009

The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of cardiovascular disease (‘antihypertensives’) in order to assess whether they meet the

Danish Medicines Agency

4-6-2009

Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation

Reimbursement status of medicinal products in ATC groups A06 and A02AA04, laxatives: Consultation responses to the Reimbursement Committee's recommendation

The Reimbursement Committee's recommendation on the future reimbursement status of laxatives (ATC groups A06 and A02AA04) has been open for consultation until 27 May 2009.

Danish Medicines Agency

4-6-2009

Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation

Reimbursement status of medicinal products in ATC group A08, antiobesity preparations, excl. diet products: Consultation responses to the Reimbursement Committee's recommendation

The Reimbursement Committee's recommendation on the future reimbursement status of antiobesity preparations, excl. diet products (ATC group A08) has been open for consultation until 25 May 2009.

Danish Medicines Agency

4-5-2009

Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

Consultation on the reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A06 (laxatives) and A02AA04 (magnesium hydroxide)

Danish Medicines Agency

30-4-2009

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC group A08 (antiobesity preparations, excl. diet products)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicinal products authorised for marketing in Denmark in ATC group A08 (antiobesity preparations, excl. diet products).

Danish Medicines Agency

2-2-2009

Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09

Consultation responses on the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09

The Danish Medicines Agency's assessment of the future reimbursement status of 5 combination products in ATC groups C07, C08 and C09 for the treatment of cardiovascular diseases has been submitted for consultation with 11 December 2008 as the consultation deadline.

Danish Medicines Agency

19-12-2008

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

Consultation responses on the future reimbursement status of dihydropyridine calcium antagonists (C08CA)

The Danish Medicines Agency's assessment of the future reimbursement status of the dihydropyridine calcium antagonists (C08CA) were submitted for consultation with 11 November 2008 as the consultation deadline.

Danish Medicines Agency

27-11-2008

Reassessment of reimbursement status for 5 combination products in ATC groups C07, C08 and C09

Reassessment of reimbursement status for 5 combination products in ATC groups C07, C08 and C09

The Danish Medicines Agency has assessed the question of the future reimbursement status for five combination products in ATC groups C07, C08 and C09 on the basis of updated information about prices and consumption of these medicinal products.

Danish Medicines Agency

21-11-2008

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline

Danish Medicines Agency

29-10-2008

Reassessment of reimbursement status for medicinal products in ATC group C08CA

Reassessment of reimbursement status for medicinal products in ATC group C08CA

The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

7-7-2008

Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases

Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases

The Reimbursement Committee's recommendation about the future reimbursement status of medicinal products for the treatment of cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensive drugs) was submitted for consultation on 5 May 2008.

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

23-5-2007

Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee

Reassessment of the reimbursement status of blood pressure products resumed in the Reimbursement Committee

At its meeting on 12 December 2006, the Reimbursement Committee resumed the reassessment of the reimbursement status of blood pressure products.

Danish Medicines Agency

29-3-2007

New reimbursement status of lipid lowering medicinal products enters into force on 23 April 2007

New reimbursement status of lipid lowering medicinal products enters into force on 23 April 2007

As of 23 April 2007, the reimbursement status of lipid lowering medicinal products will be changed. The decision includes all lipid lowering medicinal products with marketing authorisations in Denmark on 15 March 2007.

Danish Medicines Agency

15-2-2007

Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10

Reassessment of reimbursement status of medicinal products in ATC-groups A01, A04, C04, C05 and C10

In connection with the reassessment of the reimbursement status of medicinal products, the Reimbursement Committee discussed the reimbursement status of certain ATC groups at its meeting on 16 January 2007.

Danish Medicines Agency

18-12-2006

Reassessment of ATC-groups C01, C04 and C05

Reassessment of ATC-groups C01, C04 and C05

At its meeting on 19 September 2006, the Reimbursement Committee had its first discussion of the reimbursement status of the following ATC groups.

Danish Medicines Agency

18-12-2006

Reassessment of reimbursement status

Reassessment of reimbursement status

This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.

Danish Medicines Agency

18-12-2006

Reassessment of reimbursement status of ATC-groups C01, C04 and C05

Reassessment of reimbursement status of ATC-groups C01, C04 and C05

At its meetings on 19 September and 7 November 2006, the Reimbursement Committee discussed the reimbursement status of medicinal products in ATC-groups.

Danish Medicines Agency

18-12-2006

Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.

Danish Medicines Agency

24-4-2006

Letter to scientific societies on treatment of hypertension

Letter to scientific societies on treatment of hypertension

As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.

Danish Medicines Agency

7-8-2018

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

By Aug. 10, all packages and advertisements for “covered” tobacco products (except for cigars and pipe tobacco) and roll-your-own/cigarette tobacco products must have the required nicotine warning statement. https://cards.twitter.com/cards/2m2m96/5xn98 …

FDA - U.S. Food and Drug Administration